Abeona Therapeutics Has Submitted The Briefing Package To The FDA For Its Pre-biologics License Application Meeting In August 2023 Regarding The Application For EB-101, Engineered Cell Therapy For Recessive Dystrophic Epidermolysis Bullosa
Portfolio Pulse from Benzinga Newsdesk
Abeona Therapeutics has submitted the briefing package to the FDA for its pre-biologics license application meeting in August 2023. The application is for EB-101, an engineered cell therapy for Recessive Dystrophic Epidermolysis Bullosa.
July 28, 2023 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abeona Therapeutics has moved a step closer to getting FDA approval for its EB-101 therapy. This could potentially boost the company's stock in the short term.
The submission of the briefing package to the FDA is a significant step in the approval process for Abeona Therapeutics' EB-101 therapy. If the FDA approves the therapy, it could lead to increased revenues for the company, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100